1. Home
  2. PRMB vs RYTM Comparison

PRMB vs RYTM Comparison

Compare PRMB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primo Brands Corporation

PRMB

Primo Brands Corporation

HOLD

Current Price

$18.23

Market Cap

6.9B

Sector

N/A

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$102.78

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRMB
RYTM
Founded
1955
2008
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRMB
RYTM
Price
$18.23
$102.78
Analyst Decision
Buy
Strong Buy
Analyst Count
11
13
Target Price
$29.27
$129.92
AVG Volume (30 Days)
5.3M
657.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.97
$47.98
Revenue Next Year
$0.79
$56.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.36
$45.91
52 Week High
$35.85
$122.20

Technical Indicators

Market Signals
Indicator
PRMB
RYTM
Relative Strength Index (RSI) 45.54 49.11
Support Level $18.66 $95.44
Resistance Level $19.46 $110.93
Average True Range (ATR) 0.62 5.61
MACD -0.16 -0.53
Stochastic Oscillator 14.75 48.51

Price Performance

Historical Comparison
PRMB
RYTM

About PRMB Primo Brands Corporation

Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Share on Social Networks: